Collegium Pharmaceutical, Inc. (COLL)

Environment story

Collegium Pharmaceutical discloses no material environmental data regarding Scope 1, 2, or 3 emissions, net-zero targets, renewable energy procurement, or carbon mitigation initiatives. The 10-K Risk Factors section contains no environmental controversies, regulatory fines, or resource-consumption disputes. As a pharmaceutical manufacturer relying on third-party contract manufacturers (Patheon/Thermo Fisher for Xtampza ER), the company does not directly operate manufacturing facilities and has not published corporate sustainability reporting on environmental metrics. Absence of disclosed climate commitments and emissions data results in deductions for undisclosed Scope 3 emissions and missing net-zero target. No evidence of greenwashing detected, as company makes no environmental claims.

Social story

Collegium Pharmaceutical reports no disclosed diversity metrics, CEO-to-median-worker pay ratios, or turnover rates in the 10-K filing. The company does not disclose union standing, labor relations status, or documented labor disputes. 2025 operating expenses included $49.4 million in salary and wage increases due to Ironshore Acquisition headcount expansion and executive transitions involving $2.6 million in accelerated equity and $1.4 million in severance. The 10-K references litigation and regulatory investigations regarding opioid marketing practices (Master Settlement Agreement of $2.75 million in March 2022, Massachusetts Attorney General Assurance of Discontinuance in December 2021, and ongoing Civil Investigative Demands from state attorneys general). Supply-chain ethics related to controlled-substance manufacturing (oxycodone, tapentadol, buprenorphine, methylphenidate) are not audited for human-rights hazards in disclosed materials. No formal DEI program, diversity targets, or supplier diversity commitments are mentioned.

Governance story

Collegium Pharmaceutical does not disclose board independence percentage, share structure classification (single or dual-class), or annual lobbying expenditures in the 10-K filing. The company does not report PAC contributions or political engagement. No antitrust proceedings, consumer-safety fines, or SEC consent decrees are disclosed in the risk factors or MD&A. The company is engaged in active litigation with generic competitors (Paragraph IV Certifications for Belbuca, pending litigation with Purdue regarding patent validity and scope). Two significant regulatory actions are documented: (1) FDA announcement in July 2025 of mandatory labeling changes for all opioid pain medications and (2) FDA announcement in September 2025 of heightened scrutiny of DTC advertising and promotional practices with warning letters issued for allegedly misleading claims. The company reports compliance with these requirements but acknowledges heightened enforcement risk. No evidence of suing shareholder groups to block climate proposals or active deregulatory lobbying. Governance structure and independence metrics remain undisclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Collegium Pharmaceutical, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Collegium Pharmaceutical, Inc. in the app for interactive charts and portfolio building.

More in Healthcare